HCW Biologics Inc.
Close on Oct 19, 2026
- Market cap
- $1.63M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | During market hours | $135.57K | $-11.58 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | $6.50M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | After market close | $27.01K | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | $15.61K | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $6.55K | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | $5.07K | $-0.05 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 28, 2025 | During market hours | $394.80K | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | $426.42K | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 1, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | Before market open | – | – | – |
Press releases
Announcements HCW Biologics filed with the SEC
HCW Biologics Inc. Announces Pricing
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Biologics Reports Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biologics Announces 1-for-6 Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic,
Regulation FD disclosure · EX-99.1 to Form 8-K
Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biologics Reports First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
Other events · EX-99.1 to Form 8-K
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025
Results of operations · EX-99.1 to Form 8-K
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
HCW Biologics Reports Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
HCW Biologics Reports Second Quarter 2025
Results of operations · EX-99.1 to Form 8-K/A
HCW Biologics Reports Second Quarter 2025
Results of operations · EX-99.1 to Form 8-K
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
Other events · EX-99.1 to Form 8-K
We greatly appreciate your continued support and thank you for your engagement as valued members of our stockholder community.
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Other events · EX-99.1 to Form 8-K
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
Other events · EX-99.2 to Form 8-K
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
Material agreement · Other events · EX-99.1 to Form 8-K
HCW Biologics Reports First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
HCW Biologics Announces 1-for-40 Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024
Results of operations · EX-99.1 to Form 8-K
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In- Human Phase 1 Clinical Trial
Regulation FD disclosure · EX-99.1 to Form 8-K
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
Listing notice · Other events · EX-99.1 to Form 8-K
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
HCW Biologics and WY Biotech Announce
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
HCW Biologics Reports Third Quarter 2024
Results of operations · EX-99.1 to Form 8-K
HCW Biologics Reports Second Quarter 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K/A
HCW Biologics Reports Second Quarter 2024
Results of operations · EX-99.1 to Form 8-K
HCW Biologics Reports First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End
Results of operations · EX-99.1 to Form 8-K
HCW Biologics Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
HCW Biologics Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
HCW Biologics Reports First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
HCW Biologics Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
HCW Biologics Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K